The Discovery Whole-exome sequencing of intrahepatic cholangiocarcinoma (ICC) revealed that mutations in chromatin remodeling genes - particularly BAP1, ARID1A, and PBRM1 - are among the most frequent somatic alterations in this cancer.
Why This Matters These findings identify epigenetic dysregulation as a central mechanism in ICC carcinogenesis and open new avenues for targeted therapy using drugs that modulate chromatin biology, such as HDAC inhibitors and PARP inhibitors.
Scale of Impact Combining discovery and validation cohorts, mutations in at least one of these chromatin remodeling genes were found in 41% of 64 ICC specimens, making this the most frequently altered pathway identified in this cancer type.
Discovery Screen Matched tumor and normal DNA from 32 ICCs were subjected to whole-exome sequencing using the Agilent SureSelect platform with Illumina HiSeq 2000 sequencing, achieving approximately 130-fold average coverage of targeted regions.
Statistical Significance Testing A statistical framework incorporating gene length, sequence context, and mutation type was used to identify significantly mutated genes above background mutation rates, with Bonferroni and Benjamini-Hochberg corrections applied.
Prevalence Screen A separate cohort of 32 ICCs and 8 gallbladder carcinomas was sequenced for a panel of 17 candidate driver genes to confirm mutation frequencies from the discovery phase.
BAP1 (25% in Discovery) BAP1 encodes a nuclear deubiquitinase involved in chromatin remodeling. It was mutated in 8 of 32 discovery ICCs (25%) with predominantly inactivating mutations including frameshifts and splice-site alterations. BAP1 mutations had previously been reported in renal cell carcinoma and mesothelioma but not gastrointestinal cancers.
ARID1A (19%) and PBRM1 (17%) Both encode subunits of the SWI/SNF chromatin remodeling complex. ARID1A mutations had been reported in ovarian and gastric cancers; PBRM1 mutations in renal carcinoma. Their discovery in ICC established a common chromatin remodeling vulnerability across cancer types.
Mutual Non-Exclusivity Three tumors harbored mutations in multiple chromatin remodeling genes simultaneously, suggesting additive epigenetic disruption rather than epistatic redundancy in at least a subset of ICCs.
IDH1 and IDH2 Hotspot Mutations Mutations at established hotspots in IDH1 (codon 132) and IDH2 (codon 172) were found in 19% of discovery ICCs, confirmed in 22% of the prevalence screen cohort. Subjects with IDH mutations had significantly worse 3-year survival (33%) compared to wild-type (81%, p=0.0034).
FGFR2 Alterations Four somatic FGFR2 mutations were identified (13%), plus FGFR2 gene fusions (previously reported separately). These represent promising therapeutic targets given the availability of FGFR inhibitors in clinical trials and now approved for ICC.
PI3K Pathway Mutations in multiple PI3K pathway components including PIK3CA, PTEN, PIK3C2A, and PIK3C2G were found in 22% of ICCs collectively, highlighting this signaling axis as an additional therapeutic target.
HDAC Inhibitors for SWI/SNF Loss Loss of ARID1A or PBRM1 may sensitize tumors to histone deacetylase (HDAC) inhibitors, which are already in clinical use for hematologic malignancies. SWI/SNF-mutated cancers have shown vulnerability to HDAC inhibition in preclinical studies.
PARP Inhibitors for BAP1 Loss BAP1 is involved in DNA damage response pathways. BAP1-mutated cells may exhibit homologous recombination deficiency, creating vulnerability to PARP inhibitors similar to what is exploited in BRCA-mutated cancers.
IDH Inhibitors IDH inhibitors (enasidenib and olutasidenib for IDH2 and IDH1 respectively) are FDA-approved for AML and are under clinical evaluation in IDH-mutated solid tumors including ICC, with a scientific rationale directly supported by this study.
Gallbladder vs. ICC This study found that gallbladder carcinomas and ICCs have different mutational profiles. TP53 dominates in gallbladder cancer while chromatin remodeling genes dominate in ICC, suggesting these are biologically distinct and require separate therapeutic approaches.
Risk Factor Context Prior sequencing of liver fluke-associated ICCs (from Southeast Asia) did not show chromatin remodeling mutations, suggesting that genetic alterations in ICC depend on the underlying carcinogenic exposure, with implications for global treatment strategies.
Comprehensive Sequencing Studies Subsequent large-scale efforts such as the TCGA cholangiocarcinoma study and multi-institutional sequencing programs have further refined the ICC landscape, building directly on this foundational work.